Efficacy, durability, and safety of faricimab with extended dosing up to every 16 weeks in Japanese patients with diabetic macular edema: 1-year results from the Japan subgroup of the phase 3 YOSEMITE trial

PURPOSE: To evaluate efficacy, durability, and safety of faricimab in Japanese patients with diabetic macular edema (DME). STUDY DESIGN: Subgroup analysis of 2 global, multicenter, randomized, double-masked, active-comparator–controlled, phase 3 trials (YOSEMITE, NCT03622580; RHINE, NCT03622593). ME...

Descripción completa

Detalles Bibliográficos
Autores principales: Shimura, Masahiko, Kitano, Shigehiko, Ogata, Nahoko, Mitamura, Yoshinori, Oh, Hideyasu, Ochi, Haruka, Ohsawa, Shino, Hirakata, Akito
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Japan 2023
Materias:
Clinical Investigation
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9999055/
https://www.ncbi.nlm.nih.gov/pubmed/36897413
http://dx.doi.org/10.1007/s10384-023-00979-8

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9999055/
https://www.ncbi.nlm.nih.gov/pubmed/36897413
http://dx.doi.org/10.1007/s10384-023-00979-8

Ejemplares similares